This Article Full Text (OnlineFirst[PDF]) Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Google Scholar Articles by Chakravarty, A. Articles by Sridhara, R. PubMed PubMed Citation Articles by Chakravarty, A. Articles by Sridhara, R. Social Bookmarking                   What's this?

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

Office of Biostatistics, Center for Drug Evaluation and Research, FDA, MD, USA

^* To whom correspondence should be addressed.

	Abstract

There has been interest in using progression-free survival as a surrogate endpoint for overall survival in oncology clinical trials. In order to objectively define this endpoint, clear understanding of what progression means, how it is measured and what its implications are need to be discussed. This article discusses some regulatory aspects of using progression-free survival as an endpoint.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?